A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-12

Study Completion Date

2029-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is open to Japanese adults with different types of advanced cancer (solid tumors). People can join the study if their cancer has spread, and previous treatments were not successful or no treatments exist.

The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people can tolerate when taken together with an anti-PD1 antibody. The anti-PD1 antibody is already used to treat different cancers. Participants receive BI 1831169 together with an anti-PD1 antibody, which is given as an infusion into a vein for up to 1 year.

Participants visit the study site regularly. The number of site visits vary based on the study part and treatment response. Some visits include an overnight stay. The doctors regularly check the participants' health and monitor the tumors. The doctors also take note of any health problems that could have been caused by the study treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

NCT04653142

Solid Tumors

COMPLETED PHASE1

A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

NCT05370755

Patients With Advanced Solid Tumors

NOT_YET_RECRUITING PHASE1

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

NCT06091930

Gastrointestinal Cancer Lung Cancer Pancreatic Cancer +3 more

RECRUITING PHASE1

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

NCT05246995

Solid Tumor

UNKNOWN PHASE1

Study of NIB101 in Participants With Advanced Solid Tumors

NCT05192174

Solid Tumor

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

nivolumab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 1831169

Intervention Type DRUG

nivolumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumours
* Has at least 1 accessible lesion with a minimum lesion diameter (≥1 cm) for injection of BI 1831169. Lesions must either be easily accessible, or, if not easily accessible, patients must be willing to undergo repeat procedures for injections of BI 1831169.
* Has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patients must have exhausted available treatment options known to prolong survival for their disease.
* Medically fit and willing to undergo all mandatory trial procedures
* Eastern Cooperative Oncology Group (ECOG) Score of 0 or 1, and life expectancy of at least ≥3 months after the start of the treatment, according to the investigator's judgement
* Adequate organ function or bone marrow reserve as demonstrated at screening by the following laboratory values:

* Absolute neutrophil count ≥1.5x10\^9/L (≥1.5x10\^3/μL, ≥1500/mm\^3) without white blood cell growth factor support within 4 weeks of start of trial treatment; platelet count ≥100·10\^9/L (≥100·10\^3/μL, ≥100·10\^3/mm\^3), without platelet transfusion within 2 weeks of start of trial treatment
* Haemoglobin ≥90 g/L (≥9.0 g/dL, ≥5.6 mmol/L)
* Creatinine ≤1.5x upper limit of normal (ULN)
* aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3x ULN if no demonstrable liver metastases, or otherwise ≤5x ULN if transaminase elevation is attributable to liver metastases
* Total bilirubin ≤1.5x ULN, except for patients with Gilbert's syndrome: total bilirubin ≤3.0x ULN or direct bilirubin ≤1.5x ULN
* Partial thromboplastin time (PTT)/activated partial thromboplastin time (aPTT) \<1.5x ULN unless on a stable dose of an anticoagulant and no unexplained elevation of international normalised ratio (INR)
* All toxicities related to previous anti-cancer therapies (including immune related adverse event (irAEs)) have resolved to Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤1 prior to the start of trial treatment (except for alopecia, xerostomia, and immunotherapy related endocrinopathies which may be included if clinically stable on hormone supplements or antidiabetic drugs as per investigator judgement) and others per investigator judgement.

Exclusion Criteria

* Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of trial treatment
* Radiotherapy within 4 weeks prior to the start of trial treatment, except in case of a brief course of palliative radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture) which can then be completed within 2 weeks prior to start of trial treatment. Note: No radiation must have been given to any lesions planned to be injected within 6 months of start of treatment.
* Presence of brain metastases unless patient has completed brain radiotherapy and is asymptomatic. Symptomatic brain metastases, untreated malignant brain tumours and/or carcinomatous meningitis are excluded.
* Presence of other active invasive cancers other than the one to be treated in this trial within 3 years prior to screening, except for appropriately treated basal-cell carcinoma of the skin, in situ carcinoma of the uterine cervix, or other local tumours considered cured by local treatment
* Persistent toxicity from previous treatments (including irAEs) that has not resolved to Grade ≤1, except for alopecia, xerostomia, CTCAE Grade 2 neuropathy, asthenia/fatigue, or Grade 2 endocrinopathies controlled by replacement therapy
* Active or chronic hepatitis B or C infection, e.g. Hepatitis B surface antigen (HBsAg) positive or Hepatitis C antibody (anti-HCV) positive (except if hepatitis C virus (HCV)-ribonucleic acid (RNA) negative)
* Patients with history of human immunodeficiency virus (HIV) infection who meet 1 or more of the following criteria:

* cluster of differentiation 4 (CD4+) count \<350 cells/μL
* Viral load \>400 copies/mL (local lab assessment)
* Not receiving antiretroviral therapy
* Receiving established antiretroviral therapy for less than 4 weeks prior to the start of study treatment
* History of AIDS-defining opportunistic infections within 12 months prior to start of study treatment Patients with a history of HIV who do not meet any of the criteria above are eligible to participate but the patient must be under the care of an HIV/Infectious Diseases specialist or an HIV/Infectious Diseases specialist must be consulted prior to inclusion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No